Skip to main content
CTRVP
OTC Life Sciences

Stockholders Approve 27% Potential Dilution from Expanded Equity Incentive Plan

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.001
Mkt Cap
$1.5M
52W Low
$0.001
52W High
$0.001
52W Position info
0.0% above low
Off High info
at 52W high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

CTRVP is trading near its 52-week low of $0.001 (0.0% above the low).

Summary

Hepion Pharmaceuticals' stockholders approved a major expansion of its equity incentive plan, increasing the share pool by 7.8 million shares, which could lead to approximately 27% dilution for existing shareholders.


Key Events · Corporate Governance and Compliance · CTRVP

  • Equity Incentive Plan Expanded

    Stockholders approved an amendment to the 2023 Omnibus Equity Incentive Plan, increasing the number of shares issuable thereunder from 200,000 to 8,000,000.

  • Significant Potential Dilution

    The increase of 7.8 million shares represents a potential dilution of approximately 26.79% based on the 29,119,476 shares outstanding as of the record date.

  • Director Re-elections Confirmed

    Five directors, including Interim CEO Gary Stetz and Executive Chairman Vincent LoPriore, were re-elected to the board.


Analysis · CTRVP · Life Sciences

Hepion Pharmaceuticals' stockholders approved a significant expansion of its 2023 Omnibus Equity Incentive Plan, increasing the share pool by 7.8 million shares. This authorization introduces substantial potential dilution for existing shareholders, representing approximately 27% of current outstanding shares. The approval comes as the company faces a "going concern" warning, highlighting the critical need to incentivize management and employees, but at a considerable potential cost to shareholder value. This formalizes a proposal previously outlined in a DEFA14A filing on April 28, 2026.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 44.9% of the 1407 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CTRVP was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.5M. The 52-week trading range was $0.00 to $0.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CTRVP - Latest Insights

CTRVP
Oct 09, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
CTRVP
Sep 28, 2026, 6:30 AM EDT
Filing Type: 8-K
Importance Score:
8
CTRVP
Sep 10, 2026, 4:30 PM EDT
Filing Type: DEF 14C
Importance Score:
8
CTRVP
Sep 08, 2026, 5:24 PM EDT
Filing Type: 8-K
Importance Score:
8
CTRVP
Aug 27, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7